
NRx Pharmaceuticals beats EPS estimates but misses revenue, awaits FDA decisions on key drugs.
NRx Pharmaceuticals reported a quarterly EPS of -$0.04, beating estimates and improving from last year, but revenue fell short at $1.07 million. The company is preparing for an FDA decision on its Preservative-Free Ketamine and has FDA clearance for ...

